Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure  by Nanayakkara, Prabath W.B. et al.
Kidney International, Vol. 68 (2005), pp. 2230–2236
Plasma asymmetric dimethylarginine (ADMA) concentration
is independently associated with carotid intima-media thickness
and plasma soluble vascular cell adhesion molecule-1
(sVCAM-1) concentration in patients with mild-to-moderate
renal failure
PRABATH W.B. NANAYAKKARA, TOM TEERLINK, COEN D.A. STEHOUWER, DAUD ALLAJAR,
ANNEMIEKE SPIJKERMAN, CASPER SCHALKWIJK, PIET M. TER WEE, and COEN VAN GULDENER
Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; Department of Clinical Chemistry,
VU University Medical Center, Amsterdam, The Netherlands; Department of Medicine, University Hospital Maastricht, Maastricht,
The Netherlands; The Institute for Research in Extramural Medicine, VU University Medical Center, Amsterdam, The Netherlands;
Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands; and Department of Internal Medicine,
Amphia Hospital (Langendijk), Breda, The Netherlands
Plasma asymmetric dimethylarginine (ADMA) concentration
is independently associated with carotid intima-media thickness
and plasma soluble vascular cell adhesion molecule-1 (sVCAM-
1) concentration in patients with mild-to-moderate renal failure.
Background. Patients with renal insufficiency have an in-
creased risk of cardiovascular disease that is not fully explained
by the presence of known cardiovascular risk factors. In pa-
tients with end-stage renal disease, increased serum concentra-
tion of asymmetric dimethylarginine (ADMA), an endogenous
inhibitor of nitric oxide synthase (NOS), has been linked to
excess cardiovascular morbidity. We investigated, in patients
with mild-to-moderate renal failure, the relationship between
plasma ADMA and three surrogate markers of atherosclerosis
that have been shown to have prognostic value, namely carotid
intima-media thickness (IMT), plasma soluble vascular cell ad-
hesion molecule-1 (sVCAM-1), and plasma C-reactive protein
(CRP).
Methods. We used baseline data of an ongoing randomized
trial in which the effects of oxidative stress-lowering treatment
on vascular function and structure are studied in patients with
chronic nondiabetic renal failure without clinical evidence of
atherosclerosis (GFR 15 to 70 mL/min/per 1.73m2 according to
the Cockcroft-Gault equation; ATIC study).
Results. Data from 93 patients were used. Creatinine clear-
ance was inversely related to plasma ADMA concentration
(standardized b after adjustment = −0.342, P = 0.023). Plasma
ADMA was strongly related to carotid IMT in univariate (b =
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0.459, P < 0.0001) and multivariate analysis (b = 0.444, P <
0.0001). Plasma ADMA was also significantly related with
plasma soluble vascular cell adhesion molecule-1 (sVCAM-1)
in univariate (b = 0.260, P = 0.010) and multivariate (b = 0.242,
P = 0.022) analysis. Plasma ADMA was not significantly related
to C-reactive protein (b = −0.134, P = 0.204).
Conclusion. In patients with mild-to-moderate renal fail-
ure, renal function is inversely associated with plasma ADMA,
which, in turn, is positively associated with carotid IMT and
plasma sVCAM-1 concentration. Increased plasma ADMA
may be a link between renal function and cardiovascular disease
in patients with mild-to-moderate renal failure.
Patients with end-stage renal disease have an increased
risk of cardiovascular disease [1]. A similar association
exists between mild-to-moderate renal insufficiency and
cardiovascular events [2, 3]. This association is not fully
explained by the presence of known cardiovascular risk
factors such as hypertension, diabetes, smoking, homo-
cysteine level, and dyslipidemia [2, 4]. Other atherogenic
mechanisms thus seem to be active in patients with renal
insufficiency.
Asymmetric dimethylarginine (ADMA) is an en-
dogenous inhibitor of nitric oxide (NO) synthase and
is derived from the proteolysis of proteins containing
methylated arginine residues. It has considerable bi-
ological effects, particularly in the cardiovascular sys-
tem [5–7]. When administered acutely, ADMA inhibits
NO synthase catalytic activity, endothelium-dependent
NO-mediated vascular responses, and endothelium-
dependent NO bioavailability, all of which are reversed
by L-arginine [5]. The plasma concentrations of ADMA
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and its biologically inactive stereoisomer-symmetric
dimethylarginine (SDMA) are two to six times higher
in patients with end-stage renal failure than in healthy
controls [5, 8]. Plasma ADMA concentrations in dialy-
sis patients are strongly and independently related to the
intima-media thickness (IMT) of the carotid artery [9].
Carotid IMT is a strong surrogate marker of cardiovas-
cular risk in the general [10] and dialysis [11] population.
In addition, plasma ADMA concentrations are higher in
dialysis patients with clinically manifest atherosclerosis
than in those without atherosclerosis [12]. Furthermore,
ADMA levels were predictive of future cardiovascular
events and overall mortality in a cohort of patients un-
dergoing hemodialysis [13].
Data on the relationship between ADMA and cardio-
vascular disease in patients with mild-to-moderate renal
failure [glomerular filtration rate (GFR) between 10 to
70 mL/min] have not been reported. In order to gain more
insight into the mechanism of atherosclerosis in mild-to-
moderate renal failure, we therefore examined the rela-
tionship between plasma ADMA and carotid IMT, using
baseline data of the Anti-oxidant Therapy in Chronic re-
nal insufficiency (ATIC) study. In addition, we studied the
relationship between plasma ADMA on the one hand,
and plasma C-reactive protein (CRP) and plasma solu-
ble vascular cell adhesion molecule-1 (sVCAM-1) on the
other. CRP and sVCAM-1 are markers of inflammatory
activity and leukocyte-endothelial cell adhesion, respec-




Between May 2001 and December 2002, individuals
with a creatinine clearance of 15 to 70 mL/min per 1.73m2
(according to the Cockcroft-Gault equation) from seven
(six nephrology and one internal medicine) outpatient
clinics in Amsterdam, the Netherlands, were screened for
eligibility for participation in the Anti-oxidant Therapy
in Chronic renal insufficiency (ATIC) study. The ATIC
study is a randomized, double-blind, placebo-controlled
trial in which the effects of oxidative stress-lowering
treatment on vascular function and structure are stud-
ied in patients with chronic nondiabetic renal failure who
are free from manifest arterial occlusive disease. Partic-
ipants in the trial were randomized to active treatment
consisting of add-on therapy with pravastatin, vitamin
E, and homocysteine-lowering therapy, or to placebo.
Subjects not using angiotensin-converting enzyme in-
hibitors (ACE-inhibitors) or angiotensin receptor block-
ers (ARBs) at inclusion were put on ACE-inhibitors
for at least two weeks before the baseline measurement
and randomization. Those who were on ARBs contin-
ued their ARBs. We excluded individuals with diabetes
mellitus (ADA criteria), active vasculitis, nephrotic syn-
drome (>3 g/24hr urine protein), renal transplantation,
fasting total cholesterol >7 mmol/L, cholesterol-lowering
therapy within three months prior to inclusion or known
ischemic cardiac, cerebrovascular or peripheral arterial
disease. Ninety-three patients (out of 118 eligible pa-
tients) took part in the study and written informed con-
sent was obtained from all participants. Baseline data of
these individuals were used for this investigation.
Procedures
All patients were examined in the fasting state in a
supine position in a temperature-controlled room. First,
data were collected with regard to age, medication, and
smoking status (having smoked in the past year), and a
detailed history was obtained to exclude clinically rele-
vant peripheral, cerebral, and coronary vascular disease.
Thereafter, height and weight were measured with the
individuals wearing light clothing and a thorough phys-
ical examination was done. After 30 minutes of rest,
blood pressure was measured with an oscillometric device
(Colin Press-Mate, model BP-8800; Komaki-City, Japan)
and expressed as the mean value of six measurements
over a period of 30 minutes. Mean arterial pressure was
calculated as (2 diastolic pressure + systolic pressure)/3.
Blood samples were collected after 15 minutes of rest and
immediately placed on ice and centrifuged within 15 min-
utes. Plasma samples were stored at −80◦C until analysis.
Carotid ultrasonography
The carotid IMT measurements were performed using
Pie Medical Scanner 350 (Pie Medical, Maastricht, The
Netherlands) with a linear array transducer of 7.5 MHz
attached to a data registration and processing unit (Wall
Track System II). A single trained operator performed
all scans. After 15 minutes of supine rest, subjects were
examined with the head turned 30◦ to the left. B-mode
images were obtained of the right common carotid artery
at 0.5, 1, and 2 cm proximal to the bulb in the longitudinal
plane, after which an M-line was positioned perpendic-
ular to the posterior wall, showing a clear intima-media
complex. Subsequently, the system was switched to M-
mode and radiofrequency signals were collected in the
data acquisition memory of the Wall Track System, which
automatically detected and placed markers at the blood-
intima interface and media-adventitia interface on the
radiofrequency line. Radiofrequency signals of the poste-
rior wall were registered during each heartbeat triggered
by the R-top of the simultaneously recorded electrocar-
diogram. During each measurement, data obtained dur-
ing four heartbeats were analyzed separately; the mean of
these four measurements was used. Three measurements
each were performed at three locations in the common
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carotid artery and mean value of these measurements was
taken as carotid IMT.
Reproducibility
Reproducibility was assessed in 10 healthy subjects
(43 ± 13 years) who were examined by the same observer
twice, 3 weeks apart. The intraobserver coefficient of vari-
ation for the IMT measurement was 10%.
Laboratory analyses
Total cholesterol, high-density lipoprotein (HDL)
cholesterol, and triglycerides were measured by rou-
tine laboratory methods. We calculated low-density
lipoprotein (LDL) cholesterol by use of Friedewald for-
mula [18] (two participants had triglyceride levels of
>4.5 mmol/L and their LDL values were not used in
the evaluation). Serum creatinine concentration was as-
sessed by a kinetic Jaffe´ method. Plasma concentra-
tions of arginine, ADMA, and SDMA were determined
simultaneously by high-performance liquid chromatog-
raphy as described previously [19]. In short, sample
clean-up was performed by solid-phase extraction on
polymeric cation-exchange extraction columns using
monomethylarginine as internal standard. After deriva-
tization with ortho-phthaldialdehyde reagent containing
3-mercaptoproprionic acid, analytes were separated by
isocratic reversed-phase high-performance liquid chro-
matography with fluorescence detection. Analytical re-
covery was 98% to 102% and the interassay coefficient of
variation was <3%. Plasma ADMA concentration in 53
healthy individuals was 0.42 ± 0.06 lmol/L and SDMA
concentration 0.47 ± 0.08 lmol/L [19]. Plasma concen-
trations of CRP were measured with a highly sensitive
in-house enzyme-linked immunosorbent assay (ELISA)
with rabbit anti-CRP (Dako, Copenhagen, Denmark)
as a capturing and tagging antibody, with intra- and
interassay coefficients of variation of 3.8% and 4.7%,
respectively. Soluble vascular cell adhesion molecule-1
(sVCAM-1) was measured by an ELISA method (Dia-
clone, Besancon, France) with an intra- and interassay
coefficient of variation of 4.0% and 8.6%, respectively.
Plasma total (free plus protein-bound) homocysteine was
measured with an automated fluorescence polarization
immunoassay on an Abbott IMx analyzer (Abbott Lab-
oratories, Abbott Park, IL, USA), with an interassay co-
efficient of variation <4% [20].
Renal function was estimated by four methods: (1) the
serum creatinine level in lmol/L; (2) the Cockcroft-Gault
formula in mL/min per 1.73m2 [21, 22]; (3) 24-hour uri-
nary creatinine clearance in mL/min per 1.73m2; (4) the
abbreviated MDRD study equation (estimated GFR in
mL/min/1.73 m2 [186 × (Scr)−1(154 × (age)−0(203 × (0.742
if female) × (1.210 if African American)] [23].
Table 1. Baseline characteristics of the participants
N (%), mean ± SD,
N = 93 median (range)
Male gender N (%) 53 (57)
Age years 53 ± 12
Smokers N (%) 30 (36)
BMI kg/m2 26.2 ± 4.8
Blood pressure mm Hg
Systolic 136 ± 20
Diastolic 97 ± 11
Mean 79 ± 11
Pulse rate beats per minute 57 ± 13
Lipids mmol/L
Total cholesterol 5.2 ± 1.0
HDL 1.3 ± 0.4
LDL 3.2 ± 0.8
Triglycerides 1.7 ± 0.4
Renal function
Serum creatinine lmol/L 205 ± 86
Cockcroft-Gault formula mL/min/1.73m2 38 ± 15
24-hour creatinine-clearance mL/min/1.73m2 41 ± 17
MDRD formula (mL/min/1.73m2) 35 ± 14
Antihypertensive medication
ACE inhibitors—no% 58 (62)




Calcium channel blockers—no% 19 (20)
Plasma ADMA lmol/L 0.52 ± 0.07
Plasma SDMA lmol/L 1.12 ± 0.47
Plasma arginine lmol/L 96.4 ± 17.1
Plasma homocysteine lmol/L 21.3 ± 9.3
Plasma CRP mg/L 3.1 (range 0.1–85.2)
Plasma s-VCAM-1 ng/mL 959 ± 229
Intima-media thickness mm 0.67 ± 0.13
Statistical analyses
All analyses were carried out with the SPSS 11.5 soft-
ware program (SPSS, Chicago, IL, USA). Variables were
tested for normality and log transformed if necessary.
Pearson’s test was used to calculate correlation coeffi-
cients. Linear regression analysis was performed to inves-
tigate the association between estimates of renal function
and plasma ADMA concentration, and the associations
between plasma ADMA concentration and carotid IMT,
sVCAM-1, and CRP. All associations were first analyzed
without adjustments and then with adjustments for po-
tential confounders (LDL cholesterol, HDL cholesterol,
BMI, smoking, age, mean blood pressure, homocysteine)
and expressed in standardized betas. Probability values
< 0.05 were considered statistically significant.
RESULTS
Table 1 shows baseline characteristics of the partici-
pants. The causes of underlying renal disease in these pa-
tients were: hypertension (29 patients), polycystic kidney
disease (13 patients), obstructive uropathy (13 patients),
glomerulonephritis (11 patients), drug-induced (9 pa-
tients), vesico-ureteral reflux (9 patients), IgA nephropa-
thy (2 patients), and miscellaneous (7 patients).
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Fig. 1. Relationship between plasma
ADMA and creatinine clearance (Cockcroft-
Gault per 1.73m2 body surface area).
ADMA and renal function
Plasma ADMA concentration exceeded the upper
limit of the normal range of 0.54 lmol/L in 34% (32/93)
of the patients. In univariate analysis only renal function
was significantly related to plasma ADMA (standardized
b for Cockcroft-Gault clearance = −0.276, P = 0.007,
Fig. 1). After adjustments for potential confounders (age,
BMI, plasma homocysteine, smoking status, HDL, and
total cholesterol) creatinine clearance remained the only
significant determinant of plasma ADMA concentration
(b =−0.342, P = 0.023). Other estimates of renal function
gave similar results (data not shown).
ADMA and carotid IMT, CRP, and sVCAM-1
Carotid IMT was significantly related to plasma
ADMA (b = 0.459, P < 0.0001, Fig. 2), age (b = 0.407, P <
0.0001), mean arterial pressure (b =0.340, P =0.001), and
HDL cholesterol (b = −0.207, P = 0.05). There was no
significant relationship between carotid IMT and other
lipid parameters, renal function (any of the described
methods), plasma homocysteine, SDMA, sVCAM-1, or
CRP (Table 2). After adjustment for BMI, renal function,
CRP, LDL and HDL cholesterol, smoking, homocysteine,
and mean arterial pressure, the only independent deter-
minants of carotid IMT were plasma ADMA (b = 0.445,
P < 0.0001), age (b = 0.350, P < 0.0001), and mean arte-
rial pressure (b = 0.179, P = 0.05).
There was no significant relationship between plasma
ADMA and CRP in this population (b = −0.134, P =
0.204). Ten subjects had high CRP levels (>15 mg/L).
When these individuals were excluded, the relationship
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Fig. 2. Relationship between plasma asymmetric dimethylarginine
(ADMA) and carotid intima-media thickness (IMT).
0.323, P = 0.003). There was no significant relationship
between ADMA and CRP in this subgroup. Univari-
ate relationships between ADMA and carotid IMT (b =
0.403, P < 0.0001) and age and carotid IMT (b = 0.383,
P < 0.0001) were also significant in this population. Af-
ter adjustment for age, BMI, renal function, CRP, LDL
and HDL cholesterol, smoking, homocysteine, ADMA,
and mean blood pressure, only ADMA (b = 0.379, P <
0.0001), age (b = 0.335, P = 0.001), and CRP (b = 0.212,
P = 0.04) were significantly related to carotid IMT.
Plasma sVCAM-1 was significantly correlated with
plasma ADMA (b = 0.260, P = 0.010) but not with CRP
in the total population. In multiple regression analysis
with sVCAM-1 as dependent variable and ADMA, age,
2234 Nanayakkara et al: Plasma ADMA and carotid intima-media thickness in patients with chronic renal failure
Table 2. Univariate associations between carotid IMT and
cardiovascular risk factors
Standard deviation Standardized b P value
Age 12 years 0.407 <0.0001
ADMA 0.07 lmol/L 0.459 <0.0001
BMI 4.8 kg/m2 0.178 0.90
LDL-cholesterol 0.82 mmol/L 0.179 0.94
HDL-cholesterol 0.35 mmol/L −0.207 0.050
Mean blood pressure 16 mm Hg 0.340 0.001
CRP 11.1 mg/L −0.028 0.792
Creatinine clearance 15.7 mL/min/1.73m2 −0.131 0.214
(Cockcroft-Gault
formula)
Homocysteine 9.3 lmol/L 0.060 0.572
sVCAM-1 229 ng/mL 0.082 0.440
SDMA 0.47 lmol/L 0.050 0.636
The regression coefficients are expressed as standardized b (in mm) per change
of 1 standard deviation of the independent variable to facilitate direct comparison.
BMI, smoking, LDL and HDL cholesterol, renal function
(any method), and homocysteine as independent vari-
ables, only ADMA was significantly related to plasma
sVCAM-1 concentration (b = 0.245, P = 0.025). Plasma
sVCAM-1 had no significant relationship with carotid
IMT.
Plasma SDMA and renal function, homocysteine,
and ADMA
Plasma SDMA was strongly related to Cockcroft-
Gault creatinine clearance, both in univariate (b =
−0.727, P < 0.0001) and multiple regression analysis
adjusted for age, BMI, total cholesterol, and smoking
(b = −0.850 P < 0.0001). Plasma SDMA was not signifi-
cantly related to carotid IMT, CRP, or sVCAM-1. Plasma
SDMA was significantly related to plasma homocysteine
(b = 0.511, P < 0.0001) but adjustment for renal func-
tion (all four methods) weakened this association (b for
Cockcroft-Gault creatinine clearance = 0.137, P = 0.12)
DISCUSSION
In this population with mild-to-moderate nondiabetic
renal failure, renal function was inversely associated with
plasma ADMA. Plasma ADMA, in turn, was strongly
and independently associated with carotid IMT and with
plasma sVCAM-1, but not with plasma CRP.
Many authors have reported that concentrations of
ADMA are increased in patients with renal insufficiency
[5, 8, 24–26]. However, many of these studies contained
small groups of patients and patients with end stage
renal disease. In a study by Fleck et al [27], although the
mean ADMA concentration in chronic renal failure pa-
tients was 38% higher than in the healthy controls, there
was no significant correlation between plasma ADMA
and serum creatinine level in patients with chronic re-
nal failure. Kielstein et al [24] reported that ADMA
concentrations were significantly higher in patients with
renal disease (even in mild renal failure) compared with
matched controls without any overlap of ADMA con-
centrations between the two groups. They concluded that
increased ADMA levels characterize patients with renal
disease as a separate population when compared with
normotensive subjects without renal and cardiac disease.
Several observations have linked higher plasma
ADMA concentrations to atherosclerosis, cardiovascu-
lar events, and mortality in subjects who presumably
had a normal renal function [28–30] and in patients with
end-stage renal disease [13]. Bo¨ger et al [28] showed
that ADMA levels correlated strongly with the sever-
ity of atherosclerotic disease in individuals with periph-
eral arterial occlusive disease. In addition, Kielstein et al
[12] demonstrated that plasma ADMA concentrations
were higher in dialysis patients with clinically manifest
atherosclerosis than those without atherosclerosis. The
concept of a link between plasma ADMA and atheroscle-
rosis is further strengthened by studies that have shown
that plasma ADMA correlates with carotid IMT in ap-
parently healthy middle-aged individuals [29] as well as
in dialysis patients [10]. An important new finding of the
present study is that plasma ADMA was directly associ-
ated with carotid IMT in patients with mild to moderate
renal failure, suggesting that plasma ADMA may be one
of the mechanisms that link mild to moderate renal fail-
ure with cardiovascular disease [2, 3].
We measured plasma markers of inflammation (CRP)
and leukocyte-endothelial adhesion (sVCAM-1) to ex-
plore whether inflammation and/or leukocyte adhesion
to endothelial cells were related to plasma ADMA lev-
els. Plasma CRP was not significantly related to ADMA,
although it showed a significant and independent asso-
ciation with carotid IMT in subjects in whom CRP was
<15 mg/L. This suggests that, in individuals with mild-to-
moderate renal failure, the effect of ADMA on IMT is
largely unrelated to inflammatory activity insofar as this
is reflected by plasma CRP levels.
Plasma sVCAM-1 was significantly associated with
ADMA. ADMA is thought to be an important en-
dogenous NO synthase inhibitor, and inhibition of NO
synthesis is known to be associated with an increase
in endothelial adhesion molecule expression [31–34].
Therefore, one of the mechanisms that link increased
ADMA levels to atherosclerosis in individuals with mild-
to-moderate renal failure may involve up-regulation of
leukocyte adhesion molecules on endothelial cells. In a
recent study, Suda et al [35] demonstrated that coronary
microvascular lesions are induced to a comparable ex-
tent during long-term administration of ADMA in wild-
type and eNOS knockout mice. They also demonstrated
an up-regulation of ACE and increased oxidative stress
through stimulation of angiotensin-1 receptor in both
groups. They concluded that long-term vascular effects
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of ADMA might not solely be mediated by inhibition of
endothelial NO synthase. In our population, 76 subjects
used ACE-inhibitors or ARBs at inclusion; the others re-
ceived the ACE-inhibitor fosinopril before inclusion. We
did not measure the levels of ACE or oxidative stress
parameters. Therefore, we are not able to report on any
other probable mechanisms of action of ADMA in our
patients. Nevertheless, our results show that the associ-
ations of ADMA with carotid IMT and sVCAM-1 are
present even during treatment with ACE-inhibitors and
ARBs.
Plasma SDMA showed a strong and significant corre-
lation with renal function in our population. In several
other studies, the plasma SDMA level was about 3 to
8 times higher than plasma ADMA level [5, 8, 24–26].
While SDMA is almost exclusively cleared by renal ex-
cretion, ADMA is to a significant degree metabolised
by the enzyme dimethylarginine dimethylaminohydro-
lase (DDAH) [36–38]. This explains why SDMA shows
a stronger relationship with renal function than ADMA.
The biological significance of SDMA is still uncertain and
a direct inhibitory effect on NO synthase has not been
documented.
Metabolic pathways generating homocysteine and
ADMA are closely related. ADMA is generated via
posttranslational methylation of arginine residues of
proteins and these methyl groups probably come from
demeythylation process of methionine to homocysteine
[38]. Plasma ADMA had no significant relationship with
homocysteine in our population, and in the multivari-
ate analysis adjustments for homocysteine did not change
the significant relationships between ADMA and carotid
IMT, ADMA and sVCAM, and renal function and
ADMA. Plasma ADMA concentration is also raised in
young hypercholesterolemic patients with normal renal
function [39]. Adjustments for total or HDL cholesterol
also did not affect the above-mentioned relationships,
which therefore were probably independent of hyperho-
mocysteinemia or dyslipidemia.
Study limitations
We studied a small and highly selected population
of patients with mild-to-moderate renal failure and the
cross-sectional nature of the study does not permit any
final conclusions with regard to the causality of described
associations. The study was also not designed to exam-
ine new mechanisms that link increased ADMA levels
with atherothrombosis and renal failure. Therefore, we
are not able to report on any new mechanisms that ex-
plain this probable link. Most of the patients in our study
(76 patients) were on long-term ACE-inhibitors or ARBs
at the start of the study. Recent studies in patients with es-
sential hypertension and diabetes mellitus have revealed
that pharmacologic treatment with ACE inhibitors may
reduce plasma ADMA levels, possibly via enhancement
of DDAH activity [40, 41]. In addition, it has been demon-
strated that treatment with ACE inhibitors is associated
with lower plasma CRP levels [42, 43]. Therefore, use of
ACE inhibitors and ARBs in our population may have
negatively influenced the association between plasma
CRP and ADMA.
CONCLUSION
In nondiabetic patients with mild-to-moderate renal
failure without clinical features of atherosclerosis, re-
nal function showed a significant and independent re-
lationship with plasma ADMA levels which, in turn,
were associated with carotid IMT and sVCAM-1 lev-
els. The relationship of ADMA with carotid IMT was
stronger than the relationship between carotid IMT and
age. Plasma ADMA may be one of the mechanisms that
link mild-to-moderate renal failure with cardiovascular
disease.
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